CARBAGLU 200 mg DISPERSIBLE TABLETS
How to use CARBAGLU 200 mg DISPERSIBLE TABLETS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet:Information for the User
Carbaglu 200 mg dispersible tablets
carglumic acid
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the package leaflet:
- What is Carbaglu and what is it used for
- What you need to know before you take Carbaglu
- How to take Carbaglu
- Possible side effects
5 Storage of Carbaglu
- Contents of the pack and other information
1. What is Carbaglu and what is it used for
Carbaglu can help eliminate excessive plasma ammonia levels (high ammonia levels in the blood). Ammonia is especially toxic to the brain and can cause, in severe cases, a decrease in the level of consciousness and coma.
Hyperammonemia can be due to
- the lack of a specific hepatic enzyme, N-acetylglutamate synthase. Patients with this rare disorder are unable to eliminate nitrogen waste, which increases after eating proteins.
This disorder persists throughout the patient's life, so this treatment is necessary for life.
- isovaleric acidemia, methylmalonic acidemia, or propionic acidemia. Patients who suffer from one of these disorders need treatment during the hyperammonemia crisis.
2. What you need to know before you take Carbaglu
Donottake Carbaglu:
Do not take Carbaglu if you are allergic (hypersensitive) to carglumic acid or any of the other ingredients of Carbaglu (listed in section 6).
Do not take Carbaglu during breastfeeding.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Carbaglu.
Treatment with Carbaglu should be initiated under the supervision of a doctor with experience in the treatment of metabolic disorders.
Your doctor will assess your individual response to carglumic acid before starting any long-term treatment.
The dose should be adjusted individually to maintain normal ammonia levels in the blood.
Your doctor may prescribe arginine supplements or limit your protein intake.
In order to monitor your disease and treatment, your doctor may periodically examine your liver, kidneys, heart, and blood.
Other medicines and Carbaglu
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Using Carbaglu with food and drinks
Carbaglu should be taken orally before main meals or food intake.
The tablets should be dispersed in a minimum of 5 to 10 ml of water and taken immediately. The suspension has a slightly acidic taste.
Pregnancy and breastfeeding
The effects of Carbaglu on pregnancy and the fetus are unknown.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
The effects on the ability to drive and use machines are unknown.
3. How to take Carbaglu
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
Usual dose:
The initial daily dose is usually 100 mg per kilogram of body weight, up to a maximum of 250 mg per kilogram of body weight (for example, if you weigh 10 kg, you should take 1 g per day, or 5 tablets). For patients with N-acetylglutamate synthase deficiency, the long-term daily dose usually ranges from 10 mg to 100 mg per kilogram of body weight.
Your doctor will determine the suitable dose for you to maintain normal ammonia levels in your blood.
Carbaglu should be administered ONLYorally or through a nasogastric tube (using a syringe if necessary).
When the patient is in hyperammonemic coma, Carbaglu is administered by rapid push with a syringe through the tube used for feeding.
Tell your doctor if you have kidney impairment. Your daily dose should be reduced.
If you take more Carbaglu than you should
Consult your doctor or pharmacist.
If you forget to take Carbaglu
Do not take a double dose to make up for forgotten doses.
If you stop taking Carbaglu:
Do not stop taking Carbaglu without informing your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have been reported: very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), rare (may affect up to 1 in 1,000 people), very rare (may affect up to 1 in 10,000 people), and not known (cannot be estimated from the available data).
- Common:increased sweating
- Uncommon:bradycardia (decreased heart rate), diarrhea, fever, increased aminotransferases, vomiting.
- Not known:rash
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Carbaglu
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP.
The expiry date is the last day of the month stated.
Store in a refrigerator (between 2°C and 8°C).
After opening the tablet container for the first time: do not refrigerate. Do not store above 30°C.
Keep the container tightly closed to protect from moisture.
Write the opening date on the tablet container. Discard 3 months after first opening.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the pack and other information
Composition of Carbaglu
- The active substance is carglumic acid. Each tablet contains 200 mg of carglumic acid.
- The other ingredients are microcrystalline cellulose, sodium lauryl sulfate, hypromellose, sodium croscarmellose, colloidal anhydrous silica, sodium stearyl fumarate.
Appearance and packaging
Carbaglu 200 mg dispersible tablets are bar-shaped tablets with 4 divisions on one side and 3 break marks. Carbaglu is available in plastic containers of 5, 15, and 60 tablets, closed with a child-resistant cap.
Marketing authorisation holder
Recordati Rare Diseases
Immeuble “Le Wilson”
70 avenue du Général de Gaulle
F-92800 Puteaux
France
Tel.: + 33 1 4773 6458
Fax: + 33 1 4900 1800
Manufacturer
Recordati Rare Diseases
Immeuble “Le Wilson”
70, Avenue du Général de Gaulle
F-92800 Puteaux
France
or
Recordati Rare Diseases
Eco River Parc
30, rue des Peupliers
F-92000 Nanterre
France
You can request more information about this medicine from the local representative of the Marketing Authorisation Holder.
Belgium/België/Belgien Recordati Tel: +32 2 46101 36 | Lithuania Recordati AB. Tel: + 46 8 545 80 230 Sweden |
Greece Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Luxembourg/Luxemburg Recordati Tel: +32 2 46101 36 Belgium |
Czech Republic Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Hungary Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Denmark Recordati AB. Tel: +46 8 545 80 230 Sweden | Malta Recordati Rare Diseases Tel: +33 1 47 73 64 58 France |
Germany Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 | Netherlands Recordati Tel: +32 2 46101 36 Belgium |
Estonia Recordati AB. Tel: + 46 8 545 80 230 Sweden | Norway Recordati AB. Tel: +46 8 545 80 230 Sweden |
Greece Recordati Hellas Tel: +30 210 6773822 | Austria Recordati Rare Diseases Germany GmbH Tel: +49 731 140 554 0 Germany |
Spain Recordati Rare Diseases Spain S.L.U. Tel: + 34 91 659 28 90 | Poland Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
France Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 | Portugal Jaba Recordati S.A. Tel: +351 21 432 95 00 |
Croatia Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Romania Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Ireland Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France | Slovenia Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Iceland Recordati AB. Tel: +46 8 545 80 230 Sweden | Slovakia Recordati Rare Diseases Tel: +33 (0)1 47 73 64 58 France |
Italy Recordati Rare Diseases Italy Srl Tel: +39 02 487 87 173 | Finland Recordati AB. Tel: +46 8 545 80 230 Sweden |
Cyprus Recordati Rare Diseases Tel: +33 1 47 73 64 58 France | Sweden Recordati AB. Tel: +46 8 545 80 230 |
Latvia Recordati AB. Tel: + 46 8 545 80 230 Sweden | United Kingdom (Northern Ireland) Recordati Rare Diseases UK Ltd. Tel: +44 (0)1491 414333 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and treatments.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to CARBAGLU 200 mg DISPERSIBLE TABLETSDosage form: TABLET, 200 mgActive substance: carglumic acidManufacturer: Laboratorios Tillomed Spain S.L.UPrescription requiredDosage form: TABLET, 200 mgActive substance: carglumic acidManufacturer: Waymade B.V.Prescription requiredDosage form: TABLETActive substance: carglumic acidManufacturer: Recordati Rare DiseasesPrescription required
Online doctors for CARBAGLU 200 mg DISPERSIBLE TABLETS
Discuss questions about CARBAGLU 200 mg DISPERSIBLE TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions